KCTD21: A Potential Drug Target and Biomarker (G283219)

Target Name: KCTD21

NCBI ID: G283219

KCTD21

KCTD21: A Potential Drug Target and Biomarker

KCASH2, also known as KCTD21, is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the K-type ATP-binding proteins (KABP) family and is involved in a wide range of physiological processes in the body, including intracellular signaling, metabolism, and inflammation.

Recent studies have identified KCTD21 as a potential drug target in the context of several diseases, including diabetes, hypertension, and neurodegenerative disorders. Its involvement in these diseases has led to a growing interest in its potential as a biomarker for disease diagnosis and prognosis.

In addition to its potential therapeutic applications, KCTD21 has also been identified as a potential biomarker for several diseases. The KABP family is known to play a role in the regulation of intracellular signaling pathways, which are critical for the development and progression of many diseases. By targeting KCTD21, researchers may be able to gain insights into the underlying mechanisms of these diseases and identify new diagnostic tools or therapeutic targets.

One of the key challenges in studying KCTD21 as a potential drug target is its complex structure and the difficulty of predicting its functions. Despite its prevalence across various tissues, the full extent of its role in physiological processes is not yet fully understood. Additionally, the KABP family is known to be involved in a wide range of signaling pathways, making it difficult to identify specific targets that can be targeted with small molecules.

Despite these challenges, researchers have made significant progress in the study of KCTD21. Initial studies have shown that KCTD21 is involved in several intracellular signaling pathways, including the regulation of mitochondrial function, cellular metabolism, and inflammation. Additionally, several studies have identified KCTD21 as a potential drug target in the context of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic applications, KCTD21 has also been identified as a potential biomarker for several diseases. The KABP family is known to play a role in the regulation of intracellular signaling pathways, which are critical for the development and progression of many diseases. By targeting KCTD21, researchers may be able to gain insights into the underlying mechanisms of these diseases and identify new diagnostic tools or therapeutic targets.

One of the key challenges in studying KCTD21 as a potential drug target is its complex structure and the difficulty of predicting its functions. Despite its prevalence across various tissues, the full extent of its role in physiological processes is not yet fully understood. Additionally, the KABP family is known to be involved in a wide range of signaling pathways, making it difficult to identify specific targets that can be targeted with small molecules.

Despite these challenges, researchers have made significant progress in the study of KCTD21. Initial studies have shown that KCTD21 is involved in several intracellular signaling pathways, including the regulation of mitochondrial function, cellular metabolism, and inflammation. Additionally, several studies have identified KCTD21 as a potential drug target in the context of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In conclusion, KCTD21 is a protein that is expressed in various tissues of the body and is involved in a wide range of physiological processes in the body. Its potential as a drug target and biomarker has led to a growing interest in its study. Further research is needed to fully understand its role in disease and its potential as a therapeutic target.

Protein Name: Potassium Channel Tetramerization Domain Containing 21

Functions: Probable substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex mediating the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes the ubiquitination of HDAC1. Can function as antagonist of the Hedgehog pathway by affecting the nuclear transfer of transcription factor GLI1; the function probably occurs via HDAC1 down-regulation, keeping GLI1 acetylated and inactive. Inhibits cell growth and tumorigenicity of medulloblastoma (MDB) (PubMed:21472142)

The "KCTD21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCTD21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets